



COPY OF PAPERS
ORIGINALLY FILED

Attorney's Docket No.: 06275-150003 / D 1841-3P US

1617

#7B

m.m.

5/21/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Carl-Axel Bauer et al.

Art Unit : 1617

Serial No. : 10/010,283

Examiner : Jennifer Kim

Filed : November 13, 2001

Title : NEW USE FOR BUDESONIDE AND FORMOTEROL

RECEIVED

MAY 09 2002

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

RESPONSE

In response to the action mailed January 29, 2002, please amend the application as follows:

In the claims:

Cancel claims 1-8 and 10.

Amend claim 9 as follows:

R¹
9. (Amended) A method for the treatment of a patient suffering from chronic obstructive pulmonary disease, which method comprises administering to the patient via inhalation, simultaneously, sequentially or separately, a therapeutically effective amount of (i) a dose of a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; and (ii) a dose of a second active ingredient which is budesonide, wherein the molar ratio of the first active ingredient to the second active ingredient is from 1:2500 to 12:1.

←
Add new claims 11- 25.

R²
11. A method according to claim 9, wherein the first and/or second active ingredient is used in admixture with one or more pharmaceutically acceptable additives, diluents and/or carriers.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 25, 2002

Date of Deposit

Signature

Julia Doherty

Typed or Printed Name of Person Signing Certificate